NCT02078960 2021-11-09A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)Teva Branded Pharmaceutical Products R&D, Inc.Phase 1/2 Terminated10 enrolled 28 charts